Oncolytics Biotech Inc. provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC). Oncolytics' collaborator, The Pancreatic Cancer Action Network (PanCAN), a pancreatic cancer patient advocacy organization, advised the company that it is implementing a strategic re-evaluation of the Precision Promise(SM) program and will not be adding any new investigational therapies to the platform until the re-evaluation is complete. Oncolytics and PanCAN had previously planned to initiate a Phase 3 trial using the Precision Promise(SM) platform in first half of 2024.

Oncolytics now plans to conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, andatezolizumab, similar to the Precision Promise study and manage it directly within Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024. Additionally, Oncolytics and Pan CAN confirmed that PanCAN will continue with its plans to grant USD 5 million to Oncolytics as part of the Therapeutic Accelerator Award for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer patients. The company plans to provide a further update on the design of the Phase 3 trial in first half of 2024.

Oncolytics now plans to conduct an adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study and manage it directly within Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024. Additionally, Oncolytics and PanCAN confirmed that PanCAN will continue with its plans to grant USD 5 million to Oncolytics as part of the Therapeutic Accelerator Award for the new Phase 2 GOBLET study arm evaluating the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer patients.